Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatmentHilma J. van der Horst, Tuna Mutis, Esther C.W. Breij et al.|Blood Cancer Journal|2021Cited by 95
Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010Djamila E. Issa, O. Visser, S.A.M. van de Schans et al.|Haematologica|2014Cited by 57
<sup>18</sup>F-FDG or 3′-Deoxy-3′-<sup>18</sup>F-Fluorothymidine to Detect Transformation of Follicular LymphomaMariëlle J. Wondergem, Josée M. Zijlstra, Saiyada N.F. Rizvi et al.|Journal of Nuclear Medicine|2015Cited by 33
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched studyFortunato Morabito, Massimo Offidani, Sara Galimberti et al.|American Journal of Hematology|2013Cited by 26
Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple MyelomaHedwig M. Blommestein, Sonja Zweegman|JAMA Network Open|2021Cited by 15